CU24020B1 - 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6 - Google Patents

1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6

Info

Publication number
CU24020B1
CU24020B1 CU2011000101A CU20110101A CU24020B1 CU 24020 B1 CU24020 B1 CU 24020B1 CU 2011000101 A CU2011000101 A CU 2011000101A CU 20110101 A CU20110101 A CU 20110101A CU 24020 B1 CU24020 B1 CU 24020B1
Authority
CU
Cuba
Prior art keywords
piperazin
ligands
hydroxythyriptamine
arilsulfonil
benzimidazoles
Prior art date
Application number
CU2011000101A
Other languages
English (en)
Spanish (es)
Other versions
CU20110101A7 (es
Inventor
Simon N Haydar
Patrick M Andrae
Heedong Yun
Albert Jean Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24020(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CU20110101A7 publication Critical patent/CU20110101A7/es
Publication of CU24020B1 publication Critical patent/CU24020B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CU2011000101A 2008-11-11 2011-05-11 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6 CU24020B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (2)

Publication Number Publication Date
CU20110101A7 CU20110101A7 (es) 2012-01-31
CU24020B1 true CU24020B1 (es) 2014-07-30

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000101A CU24020B1 (es) 2008-11-11 2011-05-11 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6

Country Status (41)

Country Link
US (1) US8063053B2 (en:Method)
EP (1) EP2285784B1 (en:Method)
JP (1) JP5087171B2 (en:Method)
KR (1) KR101323417B1 (en:Method)
CN (1) CN102209713B (en:Method)
AP (1) AP2814A (en:Method)
AR (1) AR074325A1 (en:Method)
AU (1) AU2009314221B2 (en:Method)
BR (1) BRPI0920682A2 (en:Method)
CA (1) CA2740262C (en:Method)
CL (1) CL2011001050A1 (en:Method)
CO (1) CO6440548A2 (en:Method)
CR (1) CR20110247A (en:Method)
CU (1) CU24020B1 (en:Method)
CY (1) CY1113025T1 (en:Method)
DK (1) DK2285784T3 (en:Method)
DO (1) DOP2011000130A (en:Method)
EA (1) EA018369B1 (en:Method)
EC (1) ECSP11011045A (en:Method)
ES (1) ES2389694T3 (en:Method)
GE (1) GEP20135805B (en:Method)
HR (1) HRP20120561T1 (en:Method)
IL (1) IL212213A0 (en:Method)
MA (1) MA32788B1 (en:Method)
ME (1) ME01129B (en:Method)
MX (1) MX2011004996A (en:Method)
MY (1) MY156324A (en:Method)
NI (1) NI201100093A (en:Method)
NZ (1) NZ592563A (en:Method)
PE (1) PE20120026A1 (en:Method)
PL (1) PL2285784T3 (en:Method)
PT (1) PT2285784E (en:Method)
RS (1) RS52381B (en:Method)
SA (1) SA109300673B1 (en:Method)
SI (1) SI2285784T1 (en:Method)
SV (1) SV2011003902A (en:Method)
TN (1) TN2011000203A1 (en:Method)
TW (1) TWI481605B (en:Method)
UA (1) UA100192C2 (en:Method)
WO (1) WO2010056644A1 (en:Method)
ZA (1) ZA201103283B (en:Method)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003327A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
WO2006034312A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
EP1804799B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084207A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
KR20230002950A (ko) * 2020-04-22 2023-01-05 리커리엄 아이피 홀딩스, 엘엘씨 선택적 에스트로겐 수용체 분해제의 제조

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6316450B1 (en) * 1997-07-11 2001-11-13 Smithkline Beecham P.L.C. Compounds
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
SI0930302T1 (en) * 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ATE231857T1 (de) * 1998-08-10 2003-02-15 Winston Pharmateuticals Llc Prodrugs für proton-pump-inhibitoren
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
ATE331707T1 (de) * 2001-06-15 2006-07-15 Hoffmann La Roche 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
US7745436B2 (en) 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
BRPI0512674A (pt) 2004-07-28 2007-09-25 Irm Llc compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
DK2285784T3 (da) 2012-07-23
EA018369B1 (ru) 2013-07-30
NI201100093A (es) 2011-10-31
JP5087171B2 (ja) 2012-11-28
EA201100696A1 (ru) 2011-10-31
CA2740262C (en) 2013-05-28
SA109300673B1 (ar) 2013-05-25
CO6440548A2 (es) 2012-05-15
CR20110247A (es) 2011-06-24
JP2012508275A (ja) 2012-04-05
US8063053B2 (en) 2011-11-22
HRP20120561T1 (hr) 2012-07-31
UA100192C2 (en) 2012-11-26
ES2389694T3 (es) 2012-10-30
BRPI0920682A2 (pt) 2016-09-27
KR101323417B1 (ko) 2013-10-29
TWI481605B (zh) 2015-04-21
PL2285784T3 (pl) 2012-12-31
US20100120779A1 (en) 2010-05-13
GEP20135805B (en) 2013-04-10
CL2011001050A1 (es) 2011-08-19
WO2010056644A8 (en) 2010-11-18
WO2010056644A1 (en) 2010-05-20
CY1113025T1 (el) 2016-04-13
RS52381B (sr) 2012-12-31
EP2285784A1 (en) 2011-02-23
TN2011000203A1 (fr) 2012-12-17
CN102209713A (zh) 2011-10-05
NZ592563A (en) 2012-10-26
AR074325A1 (es) 2011-01-05
AU2009314221A1 (en) 2010-05-20
ZA201103283B (en) 2012-01-25
AU2009314221B2 (en) 2012-08-30
ME01129B (me) 2013-03-20
SV2011003902A (es) 2011-07-05
MA32788B1 (fr) 2011-11-01
SI2285784T1 (sl) 2012-08-31
PE20120026A1 (es) 2012-02-12
KR20110075013A (ko) 2011-07-05
EP2285784B1 (en) 2012-07-04
CN102209713B (zh) 2014-07-02
ECSP11011045A (es) 2011-06-30
HK1158647A1 (en) 2012-07-20
MX2011004996A (es) 2011-05-25
AP2011005664A0 (en) 2011-04-30
MY156324A (en) 2016-02-15
PT2285784E (pt) 2012-09-19
IL212213A0 (en) 2011-06-30
CU20110101A7 (es) 2012-01-31
DOP2011000130A (es) 2017-04-30
CA2740262A1 (en) 2010-05-20
TW201022247A (en) 2010-06-16
AP2814A (en) 2013-12-31

Similar Documents

Publication Publication Date Title
CU24020B1 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
UY30600A1 (es) Compuestos novedosos
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
CR11727A (es) Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina
EA201170521A1 (ru) Новые соединения
CL2011002825A1 (es) Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c.
UA104203C2 (en) Microbiocidal heterocycles
TW201000488A (en) Heterocyclic derivatives
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
CU24087B1 (es) Compuestos de carbazol
CO6670566A2 (es) Derivados de tetrahidro- pirido-pirimidina
BR112012008020A2 (pt) máquina de perfuração.
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
DOP2006000234A (es) Inhibidores de cinasa
ECSP088781A (es) Derivados de benzimidazol
DOP2006000233A (es) Inhibidores de cinasa
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина

Legal Events

Date Code Title Description
FG Grant of patent